Results 151 to 160 of about 57,759 (194)

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. [PDF]

J Clin Oncol
Gray JC, Weston R, Owens C, Canete A, Gambart M, De Wilde B, Nysom K, van Eijkelenburg N, Ladenstein R, Castellano A, Gerber NU, Marshall LV, Barone G, Rubio-San-Simon A, Ng A, Vaidya S, Gallego S, Makin G, Burke GAA, McCarthy A, Murphy D, Zwaan CM, López-Almaraz R, Jannier S, Thebaud E, Corradini N, Yeomanson D, Howell L, Tweddle DA, Elliott M, Hobin D, Valteau-Couanet D, Schleiermacher G, Chastagner P, Defachelles AS, Brichard B, George S, Chesler L, Laidler J, Firth C, Holt G, Moroz V, Pearson ADJ, Gates S, Wheatley K, Kearns P, Moreno L.   +46 more
europepmc   +1 more source

A case report on the diagnosis and treatment of a glioneuronal tumor with ATRX alteration, kinase fusion, and anaplastic features. [PDF]

Front Oncol
He S, Yang Y, Zheng J, Sun M.
europepmc   +1 more source

Association Between MGMT Promoter Methylation and Clinical and Lifestyle Factors in Glioblastoma: A Single-Center Study in Korea. [PDF]

J Clin Med
Kim MS, Lee YM, Son SA, Kim D, Lee C, Hwang JH.   +5 more
europepmc   +1 more source

Integrative machine learning-guided <i>in silico</i> and <i>in vitro</i> approach reveals selective small molecule inhibitors targeting mutant IDH1. [PDF]

RSC Adv
Bajaj M, Kumar R, Pandey V, Parvez S, Tanneru HK, Aparoy P, Karnati R.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Temozolomide

Reactions Weekly, 2021
  +8 more sources

Temozolomide

Reactions Weekly, 2022
  +5 more sources